Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Breast Cancer

Presenters

Elena Fountzilas

Citation

Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242

Authors

E. Fountzilas, G. Koliou, V. Rapti, A. Nikolakopoulos, A. Christopoulou, E. Moirogiorgou, I. Binas, G. Aravantinos, L. Kostadima, A. Nikolaidi, S. Karteri, F. Zagouri, Z. Saridaki, A. Molfeta, P. Oikonomopoulou, E. Res, D. Tryfonopoulos, G. Koumakis, G. Fountzilas, E. Razis

Author affiliations

  • Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2151

Background

Clinical trials evaluating treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with aromatase inhibitors (AI) or fulvestrant have shown promising clinical benefit in patients with advanced breast cancer. We evaluated real-world clinical outcomes and toxicity rates in patients with advanced breast cancer who received treatment with CDK4/6i in routine clinical practice.

Methods

We retrospectively reviewed medical records of patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer treated at Departments of Oncology-affiliated with the Hellenic Cooperative Oncology Group (HeCOG). All patients received hormonal therapy in combination with CDK4/6i as first-, second- or third-line of treatment and beyond. The primary end point was progression-free survival (PFS).

Results

From 07/2015 to 03/2019, 191 women were treated with CDK4/6i combined with endocrine therapy (median age: 52.2 years, postmenopausal 87, 45.5%); 86 (45%) patients received CDK4/6i in combination with AI and 105 (55%) with fulvestrant. CDK4/6i were administered as first-line treatment in 65 (34%) patients, second-line treatment in 39 (20.4%) and third-line and beyond in 83 (43.5%) patients. The median follow-up was 54.3 months (95%CI 43.0-61.2). The median PFS for patients who received first-line treatment was 18.7 months, second-line treatment 11.5 months and ≥3 lines of treatment 7.5 months. The median overall survival since the initiation of CDK4-6i treatment was 23.2 months (95% CI 20.4-30.3). The most common adverse events were neutropenia (100 patients, 52.4%) and fatigue (24, 12.6%). Grade 3-4 adverse events occurred in 55 (28.8%) patients, while 2 (1.0%) patients permanently discontinued treatment due to toxicity.

Conclusions

Among patients with HR-positive advanced breast cancer treated with CDK4/6i combined with endocrine, the estimated PFS was comparable to previously reported data. Treatment was well tolerated, with a low drug discontinuation rate.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Hellenic Cooperative Oncology Group.

Funding

Hellenic Cooperative Oncology Group (HeCOG).

Disclosure

E. Fountzilas: Travel / Accommodation / Expenses: K.A.M ONCOLOGY / HEMATOLOGY; Travel / Accommodation / Expenses: Merck; Shareholder / Stockholder / Stock options: Deciphera. G. Aravantinos: Advisory / Consultancy: Novartis; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Roche Hellas; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Genesis Pharma; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer. G. Fountzilas: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Roche; Honoraria (self): AstraZeneca. E. Razis: Honoraria (self), Advisory / Consultancy: Novartis; Travel / Accommodation / Expenses: Genesis Pharmaceuticals; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: , Bristol-Myers Squibb; Travel / Accommodation / Expenses: Genekor. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.